Oral PCSK9 Inhibitor Enlicitide Meets All Endpoints in Phase 3 Hypercholesterolemia Trial
At week 24, patients receiving once-daily enlicitide demonstrated statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol compared with placebo.
Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians
Caissa Troutman, member of the Obesity Medicine Association, emphasizes the importance of shared decision-making in overcoming barriers.
Real-World Study: Semaglutide Lowers Cardiovascular Risk More Than Tirzepatide in Adults With Obesity and CVD
At ESC 2025, the STEER study showed semaglutide reduced risk of heart attack, stroke, or death by 57% vs tirzepatide in adults with obesity and cardiovascular disease, complementing prior trial data.
FDA Approves Brensocatib for Non–Cystic Fibrosis Bronchiectasis: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Approves Subcutaneous Leqembi Autoinjector for Maintenance Therapy in Early Alzheimer Disease
The FDA has cleared Eisai and Biogen’s LEQEMBI IQLIK, the first at-home subcutaneous autoinjector for maintenance therapy in patients with early Alzheimer disease.
More Than One-Third of Middle-Aged Adults with Diabetes Prescribed GLP-1 RAs: Daily Dose
Updated COVID-19 Vaccines Are Approved, But Population Restrictions Concern Experts
Seniors remain protected along with any adult or child with underlying risk factors for severe disease, but the healthy US population is left with a choice, so far.
Spotting the Subtle Signs of Depression: How Familiarity Helps Family Physicians Excel, With Teresa Lovins, MD
Primary care clinicians see a higher share of visits for depression than mental health professionals largely because they know their patients so well, Lovins said.
8 FAQs About Vaccination From Patients With Cardiovascular Disease
Based on the FAQ section in the ACC's 2025 Concise Clinical Guideline on vaccination in adults with CVD, this short slide show also offers recommended answers.
Generic Liraglutide Approved, Marking First Generic GLP-1 RA Indicated Specifically for Weight Management in the US
Teva announced approval of the generic formulation of Saxenda, which could help expand access to the extremely popular class of antiobesity medications.
FDA Approves First New Treatment for Fibromyalgia in Over 15 Years: Daily Dose
Brief Suicide Screening in Primary Care Cut Risk by 25%: Family Physician Highlights NIMH Study
Teresa Lovins, MD, highlights a study that showed a 14% increase in rates of safety planning within 2 weeks of a negative screening led to a 25% decrease in attempted suicides.
Weekly Dose Podcast: CRC Screening Uptake, GLP-1 Eligibility in Youth, Women’s Heart Health, and Ultraprocessed Food Risks
This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.
One in Ten Individuals Initiate GLP-1 Therapy Within 5 Years of Bariatric Surgery, Study Finds
In a trial of over 112 000 US adults, researchers found that 14% started a GLP-1 receptor agonist after bariatric surgery.
American College of Cardiology: How to Address Barriers to Immunization for Adults with CVD
The ACC provides evidence-based guidance on improving vaccine uptake in vulnerable patients, addressing vaccine hesitancy, and improving overall vaccine access.
Shingles Vaccine Linked to Reduced Cardiovascular Risk in Global Meta-Analysis: ESC Preview
ESC 2025: The first global investigation of evidence for the potential positive connection is encouraging, but more research is needed to understand causality.
JN.1 COVID-19 Booster Safety Confirmed in Large Study: Daily Dose
Fall 2025 Vaccine Update: Expert Insights on Coadministration, Policy Shifts, and Hesitancy
Infectious disease and family medicine experts share guidance on vaccine policy changes, patient communication, and boosting vaccine confidence.
A Family Physician Explains Why Primary Care Can't Afford to Miss Signs of Suicide Risk
Teresa Lovins, MD, sees at least 1 or 2 patients a week who have suicidal ideation. Too many of them are at risk for an attempt within a month of those visits.
Evommune Launches Phase 2b Trial of Oral MRGPRX2 Antagonist, EVO756, In Adults With Atopic Dermatitis
MRGPRX2 antagonism is the only known mechanism of action designed to modulate mast cells and sensory neurons, both key drivers of lesions and itch in AD.
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians / Image credit: ©MJH Life Sciences")
.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Fall 2025 Vaccine Update: Expert Insights on Coadministration, Policy Shifts, and Hesitancy")
